Physician profile
Jonathan Paul Lilly
NPI 1073574414
$8,742.57
in general payments reported to CMS, 2019-2025
39 companies · $946 in 2025
The $946 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,694 · 2020: $321 · 2021: $400 · 2022: $1,351 · 2023: $1,899 · 2024: $2,130 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,975.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,997.00 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,055.16 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $902.34 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $843.27 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $369.76 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $348.14 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $332.78 | 2022-2025 | |
| Pfizer INC. | $312.72 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.34 | 2019-2024 | |
| Dexcom, INC. | $259.88 | 2023-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $251.45 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $233.21 | 2019-2023 | |
| Glaxosmithkline, LLC. | $188.70 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $156.55 | 2019-2025 | |
| Shield Therapeutics INC | $134.53 | 2024 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.